Information Analysis Inc (IAIC) 0.1550 $IAIC
Faith M. Knabe (Faith K. Goldschmidt) MA, MPH, is recognized by Continental Who's Who
PR Newswire - Tue Apr 26, 10:49AM CDT
Faith M. Knabe (Faith K. Goldschmidt) MA, MPH, is recognized by Continental Who's Who with the 2015-2016 Lifetime Achievement award as a result of fifty years of excellence in the field of Healthcare.
Information Analysis Inc. Reports Profitable Results for 2015
Marketwired - Wed Mar 30, 9:52AM CDT
Information Analysis Incorporated. (OTC PINK: IAIC) today reported results for the year ended December 31, 2015. Revenues were up 7% to $6,214,000, compared to revenues of $5,784,000 for the same period in 2014. The information technology services company reported net income of $78,000, or $0.01 per share basic and diluted, compared to a net loss of $30,000, or $(0.00) per share basic and diluted, reported for the comparable 2014 period.
Information Analysis (IAI) Announces Director of Cyber Security
ACCESSWIRE - Mon Feb 08, 12:01PM CST
FAIRFAX, VA / ACCESSWIRE / February 8, 2016 / Information Analysis Incorporated (OTC: IAIC), a business information technology services company, is pleased to announce the hiring of Irene M. Carter as its Director of Cyber Security Practice. In her role as Director, Ms. Carter will be actively involved in business development of a new technology practice for IAI centered on cyber security, secure communications and information protection.
MacAulay-Brown Wins Prime Award on Cyber Systems Technical Area Tasks IDIQ
GlobeNewswire - Mon Dec 07, 9:35AM CST
MacAulay-Brown, Inc. (MacB), a leading National Security company delivering advanced engineering services and product solutions to Defense, Intelligence, Special Operations Forces, Homeland Security and Federal agencies, announced today that it has been awarded a prime contract on the Cyber Security and Information Systems Technical Area Tasks (CS TAT) IDIQ from the Air Force Installation Contracting Agency Operating Location, Offutt AFB, Nebraska, for the Defense Technical Information Center (DTIC) Information Analysis Center. The five-year, multiple-award Indefinite-Delivery/Indefinite-Quantity (IDIQ) contract is valued at $5 billion. MacB is one of 10 defense contract winners that can bid on individual tasks estimated to be greater than $3.5 million, and work will be done at a variety of locations.
Research and Markets: Streptococcal Infections-Pipeline Insights - Provides Strategically Significant Competitor Information, Analysis, and Insights to Formulate Effective R&D Development Strategies
BusinessWire - Wed Aug 05, 2:47PM CDT
Research and Markets (http://www.researchandmarkets.com/research/4fg5ld/streptococcal) has announced the addition of the "Streptococcal Infections-Pipeline Insights" report to their offering.
Research and Markets: Clostridium Infections-Pipeline Insights - Strategically Significant Competitor Information, Analysis, and Insights to Formulate Effective R&D Development Strategies
BusinessWire - Wed Aug 05, 2:28PM CDT
Research and Markets (http://www.researchandmarkets.com/research/r4nt8z/clostridium) has announced the addition of the "Clostridium Infections-Pipeline Insights" report to their offering.
Research and Markets: Diabetic Complications-Pipeline Insights - Strategically Significant Competitor Information, Analysis, and Insights to Formulate Effective R&D Development Strategies
BusinessWire - Wed Aug 05, 1:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/8vffjm/diabetic) has announced the addition of the "Diabetic Complications-Pipeline Insights" report to their offering.
Streptococcal Infections-Pipeline Insights - Provides Strategically Significant Competitor Information, Analysis, and Insights to Formulate Effective R&D Development Strategies
M2 - Wed Aug 05, 9:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zql59x/streptococcal) has announced the addition of the "Streptococcal Infections-Pipeline Insights" report to their offering. This Streptococcal Infections-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Streptococcal Infections. This report provides information on the therapeutic development based on the Streptococcal Infections dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products. Scope - The report provides a snapshot of the global therapeutic landscape of Streptococcal Infections - The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information - Coverage of the Streptococcal Infections pipeline on the basis of target, MOA, route of administration, technology involved and molecule type - The report reviews key players involved in the therapeutics development for Streptococcal Infections and also provide company profiling - The report also gives the information of dormant and discontinued pipeline projects - Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages - Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type Key Topics Covered: - Streptococcal Infections Overview - Streptococcal Infections Pipeline Therapeutics - Streptococcal Infections Therapeutics under Development by Companies - Streptococcal Infections Late Stage Products (Filed and Phase III) - Comparative Analysis - Streptococcal Infections Mid Clinical Stage Products (Phase II) - Comparative Analysis - Streptococcal Infections Early Clinical Stage Products (Phase I and IND Filed) - Comparative Analysis - Streptococcal Infections Discovery and Pre-Clinical Stage Products - Comparative Analysis - Drug Candidate Profiles - Streptococcal Infections - Therapeutics Assessment - Assessment by Monotherapy Products - Assessment by Combination Products - Assessment by Route of Administration - Assessment by Molecule Type - Streptococcal Infections - Discontinued Products - Streptococcal Infections - Dormant Products - Companies Involved in Therapeutics Development for Streptococcal Infections For more information visit http://www.researchandmarkets.com/research/zq...eptococcal
Streptococcus Pneumoniae Infection-Pipeline Insights - Strategically Significant Competitor Information, Analysis, and Insights to Formulate Effective R&D Development Strategies
M2 - Wed Aug 05, 9:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rjgw7s/streptococcus) has announced the addition of the "Streptococcus Pneumoniae Infection-Pipeline Insights" report to their offering. This Streptococcus Pneumoniae Infection-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Streptococcus Pneumoniae Infection. This report provides information on the therapeutic development based on the Streptococcus Pneumoniae Infection dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products. Scope - The report provides a snapshot of the global therapeutic landscape of Streptococcus Pneumoniae Infection - The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information - Coverage of the Streptococcus Pneumoniae Infection pipeline on the basis of target, MOA, route of administration, technology involved and molecule type - The report reviews key players involved in the therapeutics development for Streptococcus Pneumoniae Infection and also provide company profiling - The report also gives the information of dormant and discontinued pipeline projects - Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages Key Topics Covered: - Streptococcus Pneumoniae Infection Overview - Streptococcus Pneumoniae Infection Pipeline Therapeutics - Streptococcus Pneumoniae Infection Therapeutics under Development by Companies - Streptococcus Pneumoniae Infection Late Stage Products (Filed and Phase III) - Comparative Analysis - Streptococcus Pneumoniae Infection Mid Clinical Stage Products (Phase II) - Comparative Analysis - Streptococcus Pneumoniae Infection Early Clinical Stage Products (Phase I and IND Filed) - Comparative Analysis - Streptococcus Pneumoniae Infection Discovery and Pre-Clinical Stage Products - Comparative Analysis - Drug Candidate Profiles - Streptococcus Pneumoniae Infection - Therapeutics Assessment - Assessment by Monotherapy Products - Assessment by Combination Products - Assessment by Route of Administration - Assessment by Molecule Type - Streptococcus Pneumoniae Infection - Discontinued Products - Streptococcus Pneumoniae Infection - Dormant Products - Companies Involved in Therapeutics Development for Streptococcus Pneumoniae Infection For more information visit http://www.researchandmarkets.com/research/rj...eptococcus
Clostridium Infections-Pipeline Insights - Strategically Significant Competitor Information, Analysis, and Insights to Formulate Effective R&D Development Strategies
M2 - Wed Aug 05, 9:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9mkz4d/clostridium) has announced the addition of the "Clostridium Infections-Pipeline Insights" report to their offering. This Clostridium Infections-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Clostridium Infections. This report provides information on the therapeutic development based on the Clostridium Infections dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products. Scope - The report provides a snapshot of the global therapeutic landscape of Clostridium Infections - The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information - Coverage of the Clostridium Infections pipeline on the basis of target, MOA, route of administration, technology involved and molecule type - The report reviews key players involved in the therapeutics development for Clostridium Infections and also provide company profiling - The report also gives the information of dormant and discontinued pipeline projects - Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages - Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type Key Topics Covered: - Clostridium Infections Overview - Clostridium Infections Pipeline Therapeutics - Clostridium Infections Therapeutics under Development by Companies - Clostridium Infections Late Stage Products (Filed and Phase III) - Comparative Analysis - Clostridium Infections Mid Clinical Stage Products (Phase II) - Comparative Analysis - Clostridium Infections Early Clinical Stage Products (Phase I and IND Filed) - Comparative Analysis - Clostridium Infections Discovery and Pre-Clinical Stage Products - Comparative Analysis - Drug Candidate Profiles - Clostridium Infections - Therapeutics Assessment - Assessment by Monotherapy Products - Assessment by Combination Products - Assessment by Route of Administration - Assessment by Molecule Type - Clostridium Infections - Discontinued Products - Clostridium Infections - Dormant Products - Companies Involved in Therapeutics Development for Clostridium Infections For more information visit http://www.researchandmarkets.com/research/9m...lostridium
Diabetic Complications-Pipeline Insights - Strategically Significant Competitor Information, Analysis, and Insights to Formulate Effective R&D Development Strategies
M2 - Wed Aug 05, 9:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/trbvmg/diabetic) has announced the addition of the "Diabetic Complications-Pipeline Insights" report to their offering. This Diabetic Complications-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Diabetic Complications. This report provides information on the therapeutic development based on the Diabetic Complications dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products. Scope - The report provides a snapshot of the global therapeutic landscape of Diabetic Complications - The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information - Coverage of the Diabetic Complications pipeline on the basis of target, MOA, route of administration, technology involved and molecule type - The report reviews key players involved in the therapeutics development for Diabetic Complications and also provide company profiling - The report also gives the information of dormant and discontinued pipeline projects - Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages Key Topics Covered: - Diabetic Complications Overview - Diabetic Complications Pipeline Therapeutics - Diabetic Complications Therapeutics under Development by Companies - Diabetic Complications Late Stage Products (Filed and Phase III) - Comparative Analysis - Diabetic Complications Mid Clinical Stage Products (Phase II) - Comparative Analysis - Diabetic Complications Early Clinical Stage Products (Phase I and IND Filed) - Comparative Analysis - Diabetic Complications Discovery and Pre-Clinical Stage Products - Comparative Analysis - Drug Candidate Profiles - Diabetic Complications - Therapeutics Assessment - Assessment by Monotherapy Products - Assessment by Combination Products - Assessment by Route of Administration - Assessment by Molecule Type - Diabetic Complications - Discontinued Products - Diabetic Complications - Dormant Products - Companies Involved in Therapeutics Development for Diabetic Complications For more information visit http://www.researchandmarkets.com/research/trbvmg/diabetiC
Particle Size Analyzer Market Global Distribution & Development Analysis
PRWeb - Thu May 14, 12:30PM CDT
This is a professional and in-depth study on the current state of the particle size analyzer industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The report focuses on global major leading industry players providing information such as company profiles, product picture and specification, capacity production, price, cost, Revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The particle size analyzer industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered. With 158 tables and figures the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market. This report also states import/export consumption, supply and demand figures, cost price and Revenue gross margins. Browse complete research report @ http://www.deepresearchreports.com/115211.html .
Information Analysis (IAI) Announces Reseller Agreement to Provide Secure Encryption Solutions for the Mobile World
ACCESSWIRE - Mon Jan 26, 8:00AM CST
FAIRFAX, VA / ACCESSWIRE / January 26, 2015 / Fairfax-based Information Analysis Incorporated (OTCQB: IAIC) a provider of information technology and professional services to the federal government and commercial marketplace, said it has signed an agreement to be a reseller of Protected Mobility products. Under the deal, IAI will leverage its existing customer relationships and proven presence in the government arena to provide sales and IT services to a broad base of customers in both the government and select commercial areas.
Information Analysis Inc. Reports New Contracts in the Third Quarter
Marketwired - Wed Nov 12, 10:42AM CST
Information Analysis Inc. (OTCBB: IAIC) today reported results for its third fiscal quarter ended September 30, 2014. Revenues were $1,357,000 compared to $3,218,000 reported in the third quarter 2013. The information technology services company reported net income of $28,000, or $0.00 per share basic and diluted, compared to net income of $108,000 or $0.01 per share basic and diluted, in the third quarter 2013.
Profectus BioSciences Receives $9.5 Million Department of Defense Funding to Manufacture Trivalent VesiculoVax(TM)-Vectored Vaccine to Protect Against all Ebola and Marburg Viruses
PR Newswire - Fri Oct 31, 7:00AM CDT
Profectus BioSciences, Inc., a clinical-stage vaccine company developing novel vaccines for the treatment and prevention of infectious diseases, announced today that the Department of Defense (DoD) through the Medical Countermeasure Systems-Joint Vaccine Acquisition Program (MCS-JVAP), a subordinate command of the Joint Program Executive Office for Chemical and Biological Defense, Edgewood, MD, has contracted the manufacture and IND-enabling preclinical testing of the Profectus trivalent Ebola/Marburg vaccine. In addition, the USACC has contracted for clinical evaluation of the VesiculoVax(TM) Zaire-Ebola virus vaccine to meet the current outbreak in West Africa. The $9.5 million award has been made with Battelle Memorial Institute through the Chemical, Biological, Radiological, & Nuclear Defense Information Analysis Center (CBRNIAC) contract, a Defense Technical Information Center (DTIC®) owned, Indefinite Delivery Indefinite Quantity (ID/IQ) contract vehicle for providing comprehensive scientific and technical research and analysis supporting the Department of Defense CBRN and Homeland Defense communities. Battelle has contracted with Profectus for manufacturing and clinical evaluation and with Charles River Laboratories and Biologics Consulting Group for preclinical testing and IND preparation, respectively.
Faith M. Knabe (Faith K. Goldschmidt) MA, MPH, is recognized by Continental Who's Who
PR Newswire - Tue Apr 26, 10:49AM CDT
Faith M. Knabe (Faith K. Goldschmidt) MA, MPH, is recognized by Continental Who's Who with the 2015-2016 Lifetime Achievement award as a result of fifty years of excellence in the field of Healthcare.
Information Analysis Inc. Reports Profitable Results for 2015
Marketwired - Wed Mar 30, 9:52AM CDT
Information Analysis Incorporated. (OTC PINK: IAIC) today reported results for the year ended December 31, 2015. Revenues were up 7% to $6,214,000, compared to revenues of $5,784,000 for the same period in 2014. The information technology services company reported net income of $78,000, or $0.01 per share basic and diluted, compared to a net loss of $30,000, or $(0.00) per share basic and diluted, reported for the comparable 2014 period.
Information Analysis (IAI) Announces Director of Cyber Security
ACCESSWIRE - Mon Feb 08, 12:01PM CST
FAIRFAX, VA / ACCESSWIRE / February 8, 2016 / Information Analysis Incorporated (OTC: IAIC), a business information technology services company, is pleased to announce the hiring of Irene M. Carter as its Director of Cyber Security Practice. In her role as Director, Ms. Carter will be actively involved in business development of a new technology practice for IAI centered on cyber security, secure communications and information protection.
MacAulay-Brown Wins Prime Award on Cyber Systems Technical Area Tasks IDIQ
GlobeNewswire - Mon Dec 07, 9:35AM CST
MacAulay-Brown, Inc. (MacB), a leading National Security company delivering advanced engineering services and product solutions to Defense, Intelligence, Special Operations Forces, Homeland Security and Federal agencies, announced today that it has been awarded a prime contract on the Cyber Security and Information Systems Technical Area Tasks (CS TAT) IDIQ from the Air Force Installation Contracting Agency Operating Location, Offutt AFB, Nebraska, for the Defense Technical Information Center (DTIC) Information Analysis Center. The five-year, multiple-award Indefinite-Delivery/Indefinite-Quantity (IDIQ) contract is valued at $5 billion. MacB is one of 10 defense contract winners that can bid on individual tasks estimated to be greater than $3.5 million, and work will be done at a variety of locations.
Research and Markets: Streptococcal Infections-Pipeline Insights - Provides Strategically Significant Competitor Information, Analysis, and Insights to Formulate Effective R&D Development Strategies
BusinessWire - Wed Aug 05, 2:47PM CDT
Research and Markets (http://www.researchandmarkets.com/research/4fg5ld/streptococcal) has announced the addition of the "Streptococcal Infections-Pipeline Insights" report to their offering.
Research and Markets: Clostridium Infections-Pipeline Insights - Strategically Significant Competitor Information, Analysis, and Insights to Formulate Effective R&D Development Strategies
BusinessWire - Wed Aug 05, 2:28PM CDT
Research and Markets (http://www.researchandmarkets.com/research/r4nt8z/clostridium) has announced the addition of the "Clostridium Infections-Pipeline Insights" report to their offering.
Research and Markets: Diabetic Complications-Pipeline Insights - Strategically Significant Competitor Information, Analysis, and Insights to Formulate Effective R&D Development Strategies
BusinessWire - Wed Aug 05, 1:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/8vffjm/diabetic) has announced the addition of the "Diabetic Complications-Pipeline Insights" report to their offering.
Streptococcal Infections-Pipeline Insights - Provides Strategically Significant Competitor Information, Analysis, and Insights to Formulate Effective R&D Development Strategies
M2 - Wed Aug 05, 9:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zql59x/streptococcal) has announced the addition of the "Streptococcal Infections-Pipeline Insights" report to their offering. This Streptococcal Infections-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Streptococcal Infections. This report provides information on the therapeutic development based on the Streptococcal Infections dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products. Scope - The report provides a snapshot of the global therapeutic landscape of Streptococcal Infections - The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information - Coverage of the Streptococcal Infections pipeline on the basis of target, MOA, route of administration, technology involved and molecule type - The report reviews key players involved in the therapeutics development for Streptococcal Infections and also provide company profiling - The report also gives the information of dormant and discontinued pipeline projects - Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages - Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type Key Topics Covered: - Streptococcal Infections Overview - Streptococcal Infections Pipeline Therapeutics - Streptococcal Infections Therapeutics under Development by Companies - Streptococcal Infections Late Stage Products (Filed and Phase III) - Comparative Analysis - Streptococcal Infections Mid Clinical Stage Products (Phase II) - Comparative Analysis - Streptococcal Infections Early Clinical Stage Products (Phase I and IND Filed) - Comparative Analysis - Streptococcal Infections Discovery and Pre-Clinical Stage Products - Comparative Analysis - Drug Candidate Profiles - Streptococcal Infections - Therapeutics Assessment - Assessment by Monotherapy Products - Assessment by Combination Products - Assessment by Route of Administration - Assessment by Molecule Type - Streptococcal Infections - Discontinued Products - Streptococcal Infections - Dormant Products - Companies Involved in Therapeutics Development for Streptococcal Infections For more information visit http://www.researchandmarkets.com/research/zq...eptococcal
Streptococcus Pneumoniae Infection-Pipeline Insights - Strategically Significant Competitor Information, Analysis, and Insights to Formulate Effective R&D Development Strategies
M2 - Wed Aug 05, 9:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rjgw7s/streptococcus) has announced the addition of the "Streptococcus Pneumoniae Infection-Pipeline Insights" report to their offering. This Streptococcus Pneumoniae Infection-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Streptococcus Pneumoniae Infection. This report provides information on the therapeutic development based on the Streptococcus Pneumoniae Infection dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products. Scope - The report provides a snapshot of the global therapeutic landscape of Streptococcus Pneumoniae Infection - The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information - Coverage of the Streptococcus Pneumoniae Infection pipeline on the basis of target, MOA, route of administration, technology involved and molecule type - The report reviews key players involved in the therapeutics development for Streptococcus Pneumoniae Infection and also provide company profiling - The report also gives the information of dormant and discontinued pipeline projects - Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages Key Topics Covered: - Streptococcus Pneumoniae Infection Overview - Streptococcus Pneumoniae Infection Pipeline Therapeutics - Streptococcus Pneumoniae Infection Therapeutics under Development by Companies - Streptococcus Pneumoniae Infection Late Stage Products (Filed and Phase III) - Comparative Analysis - Streptococcus Pneumoniae Infection Mid Clinical Stage Products (Phase II) - Comparative Analysis - Streptococcus Pneumoniae Infection Early Clinical Stage Products (Phase I and IND Filed) - Comparative Analysis - Streptococcus Pneumoniae Infection Discovery and Pre-Clinical Stage Products - Comparative Analysis - Drug Candidate Profiles - Streptococcus Pneumoniae Infection - Therapeutics Assessment - Assessment by Monotherapy Products - Assessment by Combination Products - Assessment by Route of Administration - Assessment by Molecule Type - Streptococcus Pneumoniae Infection - Discontinued Products - Streptococcus Pneumoniae Infection - Dormant Products - Companies Involved in Therapeutics Development for Streptococcus Pneumoniae Infection For more information visit http://www.researchandmarkets.com/research/rj...eptococcus
Clostridium Infections-Pipeline Insights - Strategically Significant Competitor Information, Analysis, and Insights to Formulate Effective R&D Development Strategies
M2 - Wed Aug 05, 9:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9mkz4d/clostridium) has announced the addition of the "Clostridium Infections-Pipeline Insights" report to their offering. This Clostridium Infections-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Clostridium Infections. This report provides information on the therapeutic development based on the Clostridium Infections dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products. Scope - The report provides a snapshot of the global therapeutic landscape of Clostridium Infections - The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information - Coverage of the Clostridium Infections pipeline on the basis of target, MOA, route of administration, technology involved and molecule type - The report reviews key players involved in the therapeutics development for Clostridium Infections and also provide company profiling - The report also gives the information of dormant and discontinued pipeline projects - Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages - Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type Key Topics Covered: - Clostridium Infections Overview - Clostridium Infections Pipeline Therapeutics - Clostridium Infections Therapeutics under Development by Companies - Clostridium Infections Late Stage Products (Filed and Phase III) - Comparative Analysis - Clostridium Infections Mid Clinical Stage Products (Phase II) - Comparative Analysis - Clostridium Infections Early Clinical Stage Products (Phase I and IND Filed) - Comparative Analysis - Clostridium Infections Discovery and Pre-Clinical Stage Products - Comparative Analysis - Drug Candidate Profiles - Clostridium Infections - Therapeutics Assessment - Assessment by Monotherapy Products - Assessment by Combination Products - Assessment by Route of Administration - Assessment by Molecule Type - Clostridium Infections - Discontinued Products - Clostridium Infections - Dormant Products - Companies Involved in Therapeutics Development for Clostridium Infections For more information visit http://www.researchandmarkets.com/research/9m...lostridium
Diabetic Complications-Pipeline Insights - Strategically Significant Competitor Information, Analysis, and Insights to Formulate Effective R&D Development Strategies
M2 - Wed Aug 05, 9:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/trbvmg/diabetic) has announced the addition of the "Diabetic Complications-Pipeline Insights" report to their offering. This Diabetic Complications-Pipeline Insights, 2014, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Diabetic Complications. This report provides information on the therapeutic development based on the Diabetic Complications dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products. Scope - The report provides a snapshot of the global therapeutic landscape of Diabetic Complications - The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information - Coverage of the Diabetic Complications pipeline on the basis of target, MOA, route of administration, technology involved and molecule type - The report reviews key players involved in the therapeutics development for Diabetic Complications and also provide company profiling - The report also gives the information of dormant and discontinued pipeline projects - Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages Key Topics Covered: - Diabetic Complications Overview - Diabetic Complications Pipeline Therapeutics - Diabetic Complications Therapeutics under Development by Companies - Diabetic Complications Late Stage Products (Filed and Phase III) - Comparative Analysis - Diabetic Complications Mid Clinical Stage Products (Phase II) - Comparative Analysis - Diabetic Complications Early Clinical Stage Products (Phase I and IND Filed) - Comparative Analysis - Diabetic Complications Discovery and Pre-Clinical Stage Products - Comparative Analysis - Drug Candidate Profiles - Diabetic Complications - Therapeutics Assessment - Assessment by Monotherapy Products - Assessment by Combination Products - Assessment by Route of Administration - Assessment by Molecule Type - Diabetic Complications - Discontinued Products - Diabetic Complications - Dormant Products - Companies Involved in Therapeutics Development for Diabetic Complications For more information visit http://www.researchandmarkets.com/research/trbvmg/diabetiC
Particle Size Analyzer Market Global Distribution & Development Analysis
PRWeb - Thu May 14, 12:30PM CDT
This is a professional and in-depth study on the current state of the particle size analyzer industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The report focuses on global major leading industry players providing information such as company profiles, product picture and specification, capacity production, price, cost, Revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The particle size analyzer industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered. With 158 tables and figures the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market. This report also states import/export consumption, supply and demand figures, cost price and Revenue gross margins. Browse complete research report @ http://www.deepresearchreports.com/115211.html .
Information Analysis (IAI) Announces Reseller Agreement to Provide Secure Encryption Solutions for the Mobile World
ACCESSWIRE - Mon Jan 26, 8:00AM CST
FAIRFAX, VA / ACCESSWIRE / January 26, 2015 / Fairfax-based Information Analysis Incorporated (OTCQB: IAIC) a provider of information technology and professional services to the federal government and commercial marketplace, said it has signed an agreement to be a reseller of Protected Mobility products. Under the deal, IAI will leverage its existing customer relationships and proven presence in the government arena to provide sales and IT services to a broad base of customers in both the government and select commercial areas.
Information Analysis Inc. Reports New Contracts in the Third Quarter
Marketwired - Wed Nov 12, 10:42AM CST
Information Analysis Inc. (OTCBB: IAIC) today reported results for its third fiscal quarter ended September 30, 2014. Revenues were $1,357,000 compared to $3,218,000 reported in the third quarter 2013. The information technology services company reported net income of $28,000, or $0.00 per share basic and diluted, compared to net income of $108,000 or $0.01 per share basic and diluted, in the third quarter 2013.
Profectus BioSciences Receives $9.5 Million Department of Defense Funding to Manufacture Trivalent VesiculoVax(TM)-Vectored Vaccine to Protect Against all Ebola and Marburg Viruses
PR Newswire - Fri Oct 31, 7:00AM CDT
Profectus BioSciences, Inc., a clinical-stage vaccine company developing novel vaccines for the treatment and prevention of infectious diseases, announced today that the Department of Defense (DoD) through the Medical Countermeasure Systems-Joint Vaccine Acquisition Program (MCS-JVAP), a subordinate command of the Joint Program Executive Office for Chemical and Biological Defense, Edgewood, MD, has contracted the manufacture and IND-enabling preclinical testing of the Profectus trivalent Ebola/Marburg vaccine. In addition, the USACC has contracted for clinical evaluation of the VesiculoVax(TM) Zaire-Ebola virus vaccine to meet the current outbreak in West Africa. The $9.5 million award has been made with Battelle Memorial Institute through the Chemical, Biological, Radiological, & Nuclear Defense Information Analysis Center (CBRNIAC) contract, a Defense Technical Information Center (DTIC®) owned, Indefinite Delivery Indefinite Quantity (ID/IQ) contract vehicle for providing comprehensive scientific and technical research and analysis supporting the Department of Defense CBRN and Homeland Defense communities. Battelle has contracted with Profectus for manufacturing and clinical evaluation and with Charles River Laboratories and Biologics Consulting Group for preclinical testing and IND preparation, respectively.
